Insight into the October carnage from several TMT-heavy hedge funds, like Whale Rock, which saw its flagship fund plummet 11% during the month.
Company is focused on endocrine disorders. Deal led by Perceptive Advisors.
Company chart and information is provided by TradingView based on 15-minute-delayed data.
Solid Biosciences Inc is a life science company. It is engaged in manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. Its lead product candidate, the SGT-001, is a gene transfer under development to restore functional dystrophin protein expression in patients' muscles. The company's pipeline products are the SB-001 and solid suit. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.
Website: | www.solidbio.com |
Email: | investors@solidbio.com |
Main Phone: | +1 617 337-4680 |
Address: | 141 Portland Street |
Address 2: | Fifth Floor |
State: | MA |
City / Town: | Cambridge |
Country: | US |
Postal Code: | 02139 |
Exchange: | NGS |
CEO: | Ilan Ganot |
Employees: | 70 |
Issuer Type: | CS - Common Stock |
Sector/Industry: | Healthcare |
NAICS: | Medicinal and Botanical Manufacturing(325411) |
Insight into the October carnage from several TMT-heavy hedge funds, like Whale Rock, which saw its flagship fund plummet 11% during the month.
Company is focused on endocrine disorders. Deal led by Perceptive Advisors.
Last Price N/A | Change $ N/A | Change % N/A | Tick N/A |
Bid N/A | Bid Size N/A | Ask N/A | Ask Size N/A |
Open N/A | High N/A | Low N/A | Prev Close N/A |
Last Trade | Volume N/A | 52 Wk Hi N/A | 52 Wk Low N/A |
Market Cap N/A | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
Shares N/A | EPS (TTM) N/A | PE Ratio N/A | Exchange N/A |